Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
N/ANon-phased studies
4(80.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Other(5)

Detailed Status

unknown5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 11 (20.0%)
N/A4 (80.0%)

Trials by Status

unknown5100%

Recent Activity

0 active trials
Showing 5 of 5
unknownnot_applicable

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia

NCT02735291
unknownphase_1

Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia

NCT03599375
unknownnot_applicable

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

NCT03564977
unknownnot_applicable

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

NCT03488160
unknownnot_applicable

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma

NCT02728882

Clinical Trials (5)

Showing 5 of 5 trials
NCT02735291Not Applicable

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia

Unknown
NCT03599375Phase 1

Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia

Unknown
NCT03564977Not Applicable

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Unknown
NCT03488160Not Applicable

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Unknown
NCT02728882Not Applicable

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma

Unknown

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5